AdipoGen Life Sciences

Pioglitazone

CHF 30.00
In stock
AG-CR1-0067-M0011 mgCHF 30.00
AG-CR1-0067-M0055 mgCHF 45.00
AG-CR1-0067-M02525 mgCHF 115.00
More Information
Product Details
Synonyms 5-[[4-[2-(5-Ethyl-2-pyridinyl)ethoxy]phenyl]methyl-2,4-thiazolidinedione
Product Type Chemical
Properties
Formula

C19H20N2O3S

MW 356.4
Merck Index 14: 7452
CAS 111025-46-8
Purity Chemicals ≥98% (HPLC)
Appearance White to off-white solid.
Solubility Soluble in DMSO (2.5 mg/ml) or dimethylformamide (DMF) (2.5 mg/ml).
Identity Determined by 1H-NMR.
InChi Key HYAFETHFCAUJAY-UHFFFAOYSA-N
Smiles CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1
Shipping and Handling
Shipping BLUE ICE
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Protect from light.
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
Description
  • Thiazolidinedione (TZD) reference compound [2, 3].
  • Selective PPARγ agonist. Selectively activates PPARγ-1 [1, 3]. 
  • Anti-diabetic  [3-5], decreasing insulin resistance in adipose tissue.
  • Is about one tenth as potent as rosiglitazone [1, 2].
  • Lipid metabolism modulator [6]. 
  • Estrogen synthesis inhibitor [7].
  • NF-κB inhibitor [8].
  • Neuroprotective [9].
Product References
  1. Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone: J. Sakamoto, et al.; BBRC 278, 704 (2000)
  2. The PPARs: from orphan receptors to drug discovery: T.M. Willson, et al.; J. Med. Chem. 43, 527 (2000)
  3. The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones: T.M. Willson, et al.; J. Med. Chem. 39, 665 (1996)
  4. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma): J.M. Lehmann, et al.; J. Biol. Chem. 270, 12953 (1995)
  5. [[omega-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents: B.C. Cantello, et al.; J. Med. Chem. 37, 3977 (1994)
  6. Pioglitazone: beyond glucose control: P. de Pablos-Velasco; Expert Rev. Cardiovasc. Ther. 8, 1057 (2010) Review
  7. Rosiglitazone and Pioglitazone Inhibit Estrogen Synthesis in Human Granulosa Cells by Interfering with Androgen Binding to Aromatase: D. Seto-Young, et al.; Horm. Metab. Res. 43, 250 (2011)
  8. Pioglitazone suppresses the lipopolysaccharide-induced production of inflammatory factors in mouse macrophages by inactivating NF-kappaB: C. Ao, et al.; Cell Biol. Int. 34, 723 (2010)
  9. Neuroprotective effects of pioglitazone in a rat model of permanent focal cerebral ischemia are associated with peroxisome proliferator-activated receptor gamma-mediated suppression of nuclear factor-κB signaling pathway: H.L. Zhang, et al.; Neuroscience 176, 381 (2011)
  10. Wnt/b-catenin signaling modulates human airway sensitization induced by b2-adrenoceptor stimulation: C. Faisy, et al.; PLoS One 9, e111350 (2014)
  11. PPARβ/δ recruits NCOR and regulates transcription reinitiation of ANGPTL4: N. Legrand, et al.; Nucleic Acids Res. 47, 9573 (2019)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.